Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Basal Cell Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Johns Hopkins Hospital, Baltimore, Maryland, United States
Contact: Principal Investigator (Evan Lipson, MD)
Study leads
Evan J Lipson, M.D.
Principal Investigator
Johns Hopkins University